The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Web

Nov. 12, 2019

SCIENTIFIC

The KRAS G12C inhibitor AMG 510 is showing efficacy in early clinical trials of NSCLC (passim). Mechanistic studies indicate enhancement of anti-tumour immunity in addition to direct cell killing.

https://www.nature.com/articles/s41586-019-1694-1